Polygenic risk for immuno-metabolic markers and specific depressive symptoms: A multi-sample network analysis study

Nils Kappelmann^{1,2}, Darina Czamara¹, Nicolas Rost^{1,2}, Sylvain Moser^{1,2}, Vanessa Schmoll¹, Lucia Trastulla¹, Jan Stochl^{3,4}, Susanne Lucae⁵, CHARGE inflammation working group, Elisabeth B. Binder¹, Golam M. Khandaker^{3,6,7,8,*}, & Janine Arloth^{1,9,*}

 ¹Department of Translational Research in Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany
 ²International Max Planck Research School for Translational Psychiatry (IMPRS-TP), Munich, Germany
 ³Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom
 ⁴Department of Kinanthropology, Charles University, Prague, Czech Republic
 ⁵Max-Planck-Institute of Psychiatry, Munich, Germany
 ⁶Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, United Kingdom
 ⁷MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
 ⁸Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
 ⁹Institute of Computational Biology, Helmholtz Zentrum Munich, Neuherberg, Germany

*joint senior authors

Corresponding author:

Nils Kappelmann Max-Planck-Institute of Psychiatry Kraepelinstraße 2-10 80804 Munich, Germany

Email: nils_kappelmann@psych.mpg.de; n.kappelmann@gmail.com

Abstract word count: 399

Manuscript word count: 6,306

Tables and Figures: 2 Tables and 3 Figures

Online Supplementary Tables and Figures: 7 Tables and 9 Figures

1 ABSTRACT

2 Background

3 About every fourth patient with major depressive disorder (MDD) shows evidence of systemic 4 inflammation. Previous studies have shown inflammation-depression associations of multiple 5 serum inflammatory markers and multiple specific depressive symptoms. It remains unclear, 6 however, if these associations extend to genetic/lifetime predisposition to higher inflammatory 7 marker levels and what role metabolic factors such as Body Mass Index (BMI) play. It is also 8 unclear whether inflammation-symptom associations reflect direct or indirect associations, which 9 can be disentangled using network analysis. 10 **Methods** 11 This study examined associations of polygenic risk scores (PRSs) for immuno-metabolic markers 12 (C-reactive protein [CRP], interleukin [IL]-6, IL-10, tumour necrosis factor [TNF]- α , BMI) with 13 seven depressive symptoms in one general population sample, the UK Biobank study 14 (n=110,010), and two patient samples, the Munich Antidepressant Response Signature (MARS, 15 n=1,058) and Sequenced Treatment Alternatives to Relieve Depression (STAR*D, n=1,143) 16 studies. Network analysis was applied jointly for these samples using fused graphical least 17 absolute shrinkage and selection operator (FGL) estimation as primary analysis and, individually, 18 using unregularized model search estimation. Stability of results was assessed using 19 bootstrapping and three consistency criteria were defined to appraise robustness and replicability 20 of results across estimation methods, network bootstrapping, and samples.

21 Results

Network analysis results displayed to-be-expected PRS-PRS and symptom-symptom associations
(termed edges), respectively, that were mostly positive. Using FGL estimation, results further

24 suggested 28, 29, and six PRS-symptom edges in MARS, STAR*D, and UK Biobank samples, 25 respectively. Unregularized model search estimation suggested three PRS-symptom edges in the 26 UK Biobank sample. Applying our consistency criteria to these associations indicated that only 27 the association of higher CRP PRS with greater changes in appetite fulfilled all three criteria. 28 Four additional associations fulfilled at least two consistency criteria; specifically, higher CRP 29 PRS was associated with greater fatigue and reduced anhedonia, higher TNF- α PRS was 30 associated with greater fatigue, and higher BMI PRS with greater changes in appetite and 31 anhedonia. Associations of the BMI PRS with anhedonia, however, showed an inconsistent 32 valence across estimation methods. 33 **Conclusions**

Genetic predisposition to higher systemic inflammatory markers are primarily associated with somatic/neurovegetative symptoms of depression such as changes in appetite and fatigue, consistent with previous studies based on circulating levels of inflammatory markers. We extend these findings by providing evidence that associations are direct (using network analysis) and extend to genetic predisposition to immuno-metabolic markers (using PRSs). Our findings can inform selection of patients with inflammation-related symptoms into clinical trials of immunemodulating drugs for MDD.

41

Keywords: Depression; Depressive Symptoms; Inflammation; C-reactive protein; Body Mass
Index; Interleukin 6; Interleukin 10; Tumour Necrosis Factor-α; Network Analysis

44 INTRODUCTION

45 Recent findings suggest that every fourth patient with Major Depressive Disorder (MDD) shows 46 evidence of systemic, low-grade inflammation as indicated by elevated (>3mg/L) C-reactive 47 protein (CRP) concentrations (Osimo et al., 2019). This association has been supported by cross-48 sectional case-control studies synthesised in multiple meta-analyses (Dowlati et al., 2010; 49 Goldsmith et al., 2016; Haapakoski et al., 2015; Howren et al., 2009; Köhler et al., 2017) as well 50 as longitudinal studies (Khandaker et al., 2014; Lamers et al., 2020; Mac Giollabhui et al., 2020). 51 Clinically, patients with evidence of inflammation do not respond as well to standard 52 monoaminergic and psychotherapeutic treatments (Liu et al., 2020; Lopresti, 2017). These 53 patients may, however, benefit from alternative treatment with immune-modulating drugs 54 (Kappelmann et al., 2018; Köhler-Forsberg et al., 2019; Wittenberg et al., 2020). To prioritise 55 drug and patient selection for clinical trials, it is crucial to further understand immunological and 56 clinical complexity of inflammation-symptom associations, which may allow shortlisting of 57 promising immunotherapeutic drug targets and could highlight patients with a profile of 58 inflammation-related depression.

59 Regarding immunological complexity, studies have reported various associations of serum 60 inflammatory proteins with depression, including among others CRP, interleukin (IL)-6, IL-10, 61 and tumour necrosis factor (TNF)- α (Goldsmith et al., 2016; Haapakoski et al., 2015; Köhler et 62 al., 2017). Evidence from in-depth immunophenotyping further suggests that there may be 63 distinct subgroups of inflammation-related depression as shown by immune cell count clustering 64 and transcriptome analyses (Cattaneo et al., 2020; Lynall et al., 2020). These studies suggest that 65 elevated serum levels of inflammatory markers are associated with depression, but associations of 66 depression with genetic/lifetime predisposition to higher inflammatory markers has been studied

67 less frequently and primarily for CRP (Badini et al., 2020; Kappelmann et al., 2021; Milaneschi 68 et al., 2017b, 2016). Elevated serum levels of inflammatory markers also conflate tonic and 69 phasic levels of inflammatory markers while genetic/lifetime predisposition to inflammatory 70 markers specifically maps their tonic levels. This differentiation could be relevant as highlighted 71 by research into tonic versus phasic dopamine levels (see Bilder et al., 2004), whereby tonic 72 levels regulate the amplitude of the phasic response, which has unique consequences for 73 downstream signalling. Lastly, inflammatory markers such as CRP are influenced by metabolic 74 factors (Timpson et al., 2011), which may causally underlie some inflammation-symptom 75 associations (Kappelmann et al., 2021), so a combined investigation of immuno-metabolic factors 76 is needed to disentangle their etiological roles. 77 Regarding clinical complexity, most prior research has restricted its investigation of the 78 inflammation-depression association to complexity on one side, that is focusing on multiple 79 immune markers (e.g., cell counts/ serum cytokine levels) while studying a composite depression 80 phenotype (Goldsmith et al., 2016; Haapakoski et al., 2015; Köhler et al., 2017) or focusing on 81 multiple depressive symptoms or symptom groups in the context of a single inflammatory marker (mostly CRP) (Badini et al., 2020; Jokela et al., 2016; Köhler-Forsberg et al., 2017; Lamers et al., 82 83 2020, 2019; White et al., 2017). Among studies focusing on individual symptoms, results have 84 highlighted associations of inflammatory markers with specific depressive symptoms of fatigue, 85 changes in appetite, anhedonia, and suicidality (Badini et al., 2020; Chu et al., 2019; Jokela et al., 86 2016; Kappelmann et al., 2021; Köhler-Forsberg et al., 2017; Lamers et al., 2020, 2018; 87 Milaneschi et al., 2017a; Simmons et al., 2018; White et al., 2017). However, most of these 88 studies have considered associations of inflammatory markers with each depressive symptom in 89 isolation (Chu et al., 2019; Jokela et al., 2016; Kappelmann et al., 2021; Köhler-Forsberg et al., 90 2017; Lamers et al., 2018; White et al., 2017). Although these prior approaches have led to

91 important findings, they cannot address potential causal interactions between symptoms, thus
92 conflate evidence for indirect and direct associations. For example, analyses of isolated
93 symptoms could hypothetically provide evidence for associations of CRP with both fatigue and
94 sleep problems even if CRP was only indirectly associated with fatigue *via* its effect on sleep
95 problems. A network-based approach provides one means of disentangling such direct from
96 indirect inflammation-symptom associations.

97 Network theory and related analysis techniques have recently been put forward to accommodate 98 the symptomatic complexity of mental disorders (Borsboom, 2017). Network theory proposes 99 putative causal interactions between symptoms (e.g., fatigue *causing* concentration problems 100 causing low mood), which could result in self-reinforcing vicious symptom cycles triggering and 101 maintaining mental disorders. Such associations have been investigated in an increasing amount 102 of studies on psychological symptom networks (Contreras et al., 2019; Robinaugh et al., 2020). 103 To accommodate etiological factors beyond symptoms, however, recent work has proposed an 104 expansion of symptom networks to so-called 'multi-plane' networks, for instance also including 105 genetic, metabolic, immunological, or environmental variables (Guloksuz et al., 2017). To our 106 knowledge, so far, two studies have evaluated such multi-plane networks in the context of 107 inflammation and depression by jointly analysing serum CRP (plus IL-6 & TNF-α in the study of 108 Fried et al., 2019), BMI, and potential covariates with individual depressive symptoms (Fried et 109 al., 2019; Moriarity et al., 2020a). The most consistently replicated findings between these two 110 studies suggested unique associations of CRP with fatigue and changes in appetite. A third study 111 has recently also provided evidence that the symptom structure itself was a function of CRP 112 levels; that is, interconnections between symptoms were moderated by CRP (Moriarity et al., 113 2020b). All of these previous studies were based on serum markers for inflammatory proteins, 114 however, reflective of acutely elevated inflammatory activity. Therefore, it remains unclear if

inflammation-symptom associations generalise to genetic/lifetime predisposition to higherimmuno-metabolic marker levels.

117	In the present study, we explored associations of polygenic risk scores (PRSs) for four major pro-
118	and anti-inflammatory markers (i.e., CRP, IL-6, IL-10, & TNF-α) and Body Mass Index (BMI),
119	as a metabolic marker, with individual depressive symptoms using a multi-sample, multi-plane
120	network analysis approach. We evaluated associations in three large samples including the
121	inpatient Munich Antidepressant Response Signature (MARS) study (n=1,058), the outpatient
122	Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (n=1,143), and the
123	general population UK Biobank cohort (n=110,010) (Hennings et al., 2009; Rush et al., 2004;
124	Sudlow et al., 2015). This investigation aimed to contribute to the study of inflammation and
125	depression by simultaneously addressing (i) combined immunological and symptom complexity
126	(using network analysis), (ii) unclarity regarding the influence of genetic/lifetime predisposition
127	to higher immuno-metabolic marker levels on depression (defining immuno-metabolic markers
128	using PRSs), and (iii) issues of replicability and generalisability (testing associations in one large
129	general population and two clinical samples).

130 METHODS

131 An overview of the study design and analytic procedure is presented in Figure 1.

132 -Figure 1-

133 Study samples

134 The Munich Antidepressant Response Signature (MARS) study was a naturalistic, observational

135 study of inpatients with major depressive disorder (MDD) or bipolar disorder conducted between

136 2000 and 2015 in three Southern German hospitals (Hennings et al., 2009). Based on an original

137 sample of 1,411 patients, the present study included 1,058 patients of European decent with an

138 ICD diagnosis of MDD (F32 and F33 codes) and genetic and depressive symptom data.

139 The STAR*D trial (identifier: NCT00021528) was a multisite, multistep, randomised controlled

140 trial (RCT), conducted from 2000 to 2004, evaluating different treatment options and sequences

141 for outpatients suffering from DSM-IV MDD without psychotic features (Rush et al., 2004).

142 Based on an original sample of 1,953 patients who took part in the STAR*D genetics study, the

143 present study included 1,143 individuals of European decent with genetic and depressive

144 symptom data.

145 The UK Biobank is a general population cohort including more than 500,000 individuals,

146 recruited from 2006 to 2010, with genotyping and in-depth phenotyping information (Bycroft et

147 al., 2018). More than 150,000 individuals from the initial sample took part in a follow-up mental

health survey (Davis et al., 2020) and we included a subset of 110,010 individuals that were of

149 European decent and had available genetic and depressive symptom data.

150 Ethics approval and informed consent

151 MARS received local ethics approval from Ludwig Maximilians University Munich (Hennings et 152 al., 2009). STAR*D received ethics approval from 14 participating institutional review boards, a 153 National Coordinating Center, a Data Coordinating Center, and the Data Safety and Monitoring 154 Board at the National Institute of Mental Health (Rush et al., 2006, 2004). The UK Biobank study 155 received ethics approval from North West Centre for Research Ethics Committee and Human 156 Tissue Authority research tissue bank (Bycroft et al., 2018); this project was approved under 157 project no. 26999. All three studies collected informed consent from participants prior to study 158 participation.

159 **Depressive symptom assessment**

Depressive symptoms were assessed differently across the three samples. MARS and STAR*D
studies used the observer-rated Hamilton Rating Scale for Depression (HAM-D) (Hamilton,

162 1986) while the UK Biobank study used the self-report Patient Heath Questionnaire (PHQ)-9

163 (Löwe et al., 2004). From these questionnaires, we selected seven depressive symptoms for joint

analyses across samples. These symptoms included completely overlapping symptoms of

depressed mood, anhedonia, fatigue, and suicidality, but also partially overlapping symptoms of

166 sleep problems, changes in appetite, and psychomotor changes. Supplementary Table 1 provides

167 an item-level overview of depressive symptoms and Supplementary Table 2 displays symptom

168 coding, where this differed from original Likert scale ratings.

169 Regarding partially overlapping symptoms of sleep problems, changes in appetite, and

170 psychomotor changes, the PHQ-9 only assesses information on conflated symptoms (e.g.,

171 insomnia and hypersomnia are conflated to sleep problems) while the HAM-D incorporates

172 disaggregated symptoms. To harmonise these symptom data for retention in network analyses,

173	we conflated HAM-D symptoms of psychomotor retardation and agitation to "psychomotor
174	changes". For sleep problems and changes in appetite (available in the PHQ-9), only insomnia
175	and loss of appetite are available in the HAM-D, so we included both conflated and
176	unidirectional symptoms in network analyses as previous studies have specifically highlighted
177	associations of inflammation with these symptoms (Jokela et al., 2016; Milaneschi et al., 2017b).
178	We reasoned that comparative appraisal of associations, for example with changes in appetite and
179	loss of appetite, could give further indications on potential specificity of associations to symptom
180	directions, as observed in previous reports (Kappelmann et al., 2021; Milaneschi et al., 2021b,
181	2021a).
182	We also note that we have not included items of "guilt or self-blame" from the respective studies
183	in our analyses as we considered the item content of HAM-D and PHQ-9 too distinct.

184 Specifically, the HAM-D conflates feelings of guilt with delusions of guilt and death, thus

185 moving towards psychotic symptomatology. Contrary to this, the PHQ-9 also includes "feelings

186 of inadequacy" about oneself, which are not covered by the HAM-D item.

187 Genotyping, quality control and imputation

188 We provide detailed information on genotyping, quality control and imputation procedures in the

189 Supplementary Methods. Briefly, genotyping in the MARS study was conducted using three

190 genotyping arrays across the recruitment period (see Supplementary Figure 1), the Illumina 610k

191 (n=548), Illumina OmniExpress (n=284) and Illumina GSA (n=226) arrays. In STAR*D,

192 genotyping was conducted using the Affymetrix Human Mapping 500K Array Set (n=979) and

- 193 the Affymetrix Genome-Wide Human SNP Array 5.0 (n=969) that displayed a concordance of
- 194 >99%; described in detail by Garriock *and colleagues* (2010). In the UK Biobank study, samples
- 195 were genotyped on the UK BiLEVE Axiom Array or the Affymetrix UK Biobank Axiom Array

- 196 (Bycroft et al., 2018). Following imputation in all samples, single nucleotide polymorphisms
- 197 (SNPs) with info-metric>0.6, minor allele frequency (MAF)>1%, genotyping missingness<2%,
- and no deviation from Hardy-Weinberg Equilibrium (MARS & STAR*D: $P>1e^{-5}$; UK Biobank:
- 199 $P > 1e^{-7}$) were retained.

200 **Polygenic risk scores**

201 Immuno-metabolic marker selection and GWAS data sources

- 202 PRSs for CRP, IL-6, IL-10, TNF-α, and BMI were computed based on available summary
- statistics from genome-wide association studies (GWAS; Ahola-Olli et al., 2017; Ligthart et al.,
- 204 2018; Locke et al., 2015). These inflammatory markers were selected, because (i) they showed
- 205 robust differences in case-control studies; (ii) CRP, IL-6, and TNF- α have been the most
- frequently investigated inflammatory markers overall in the context of depression; and (iii) IL-10
- 207 was the most frequently studied anti-inflammatory cytokine, so could be informative on direction
- 208 of associations between depressive symptoms and innate immune activity (Köhler et al., 2017;

209 Osimo et al., 2019). BMI was selected as the most frequently investigated metabolic marker.

- 210 GWAS data for CRP were obtained from a large GWAS of 88 studies including 204,402
- 211 individuals of European decent (Ligthart et al., 2018). GWAS data for IL-6, IL-10, and TNF-α
- 212 were obtained from a GWAS of 8,293 Finns (Ahola-Olli et al., 2017); of note, Finns have
- 213 Siberian ancestry (Lamnidis et al., 2018), which leads to a divergence from European ancestry of
- 214 our analytic samples. GWAS data for BMI were obtained from the Genetic Investigation of
- 215 Anthropometric Traits (GIANT) consortium that included up to 322,154 individuals of European
- decent (Locke et al., 2015).

217 **PRS** computation

218	PRSs can be computed by summing the GWAS association estimates of risk alleles for each
219	individual. Classically, this summation is done using an approach termed "clumping and
220	thresholding" (C+T), which first reduces summary statistics to independent SNPs and then
221	applies one or multiple thresholds (usually based on P-values) to restrict summation to SNPs with
222	high evidence for associations with phenotypes (Choi et al., 2020). As the optimal threshold for
223	the C+T approach is unknown and should ideally be estimated in a separate dataset with available
224	phenotype data, we computed PRSs using the Bayesian regression and continuous shrinkage
225	priors (PRS-CS) approach, which has been shown to perform similar to or outperform other PRS
226	computation approaches such as C+T (Ge et al., 2019; Ni et al., 2020).
227	PRS-CS takes a linkage disequilibrium (LD) reference panel into account (we used European
228	ancestry data from 1000 Genomes Project phase 3 samples) to update SNP effect sizes in a
229	blocked fashion, thus providing accurate LD adjustment. We pre-specified the global shrinkage
230	parameter \Box using suggested defaults for less polygenic (\Box =1e ⁻⁴) and more polygenic (\Box =1e ⁻²)
231	phenotypes as $\Box = 1e^{-4}$ for CRP, IL-6, IL-10, and TNF- α , and as $\Box = 1e^{-2}$ for BMI; see details in
232	Supplementary Methods. Following PRS computation in individual samples, polygenic scores
233	were corrected for age, sex, and the first two genotyping principal or multidimensional scaling
234	(MDS) components using linear regression; two genotyping principal or MDS components were
235	selected as visual inspection of component inter-correlations did not suggest evidence for
236	population stratification. Genotyping MDS components were computed based on raw Hamming-
237	distances in MARS and STAR*D, and using principal component analysis on high-quality,
238	unrelated individuals in the UK Biobank sample (Bycroft et al., 2018). PRSs in MARS were
239	additionally corrected for the genotyping array. Following computation, higher PRSs reflect
240	higher genetic predisposition to respective immuno-metabolic phenotype levels.

241 **PRS evaluation**

242	In Supplementary Table 3, we provide the number of SNPs included in PRS computation in each
243	sample, which was approximately around one million SNPs for each phenotype-sample
244	combination. The proportion of SNP overlap between samples (for the same phenotype) was
245	>0.89 suggesting that mostly overlapping SNPs contributed to PRSs (Supplementary Table 4).
246	Taking these overlapping SNP sets, correlations between the posterior SNP effect sizes between
247	samples were large for CRP (Pearson's <i>r</i> range: 0.69-0.76) and BMI (Pearson's <i>r</i> range: 0.79-
248	0.80) and relatively smaller for IL-6, IL-10, and TNF- α (Pearson's <i>r</i> range: 0.41-0.46; see
249	Supplementary Table 5). This suggests polygenic risk was quantified more similarly across
250	samples for CRP and BMI as compared to IL-6, IL-10, and TNF- α .
251	We quantified the impact that pre-specification of the hyperparameter \Box had on resulting PRSs,
252	which was likely small (Supplementary Table 6). Specifically, PRSs with pre-specified \Box
253	exhibited large correlations with PRSs based on automatic learning of \Box from GWAS summary
254	data (termed PRS-CS-auto in the literature; Pearson's r range: 0.82-0.98). Furthermore,
255	moderate-to-large correlations remained to PRSs based on extreme grid search boundary values
256	of \Box (Pearson's <i>r</i> range: 0.47-0.93).
257	Since MARS utilised three different genotyping arrays, we verified that our approach of
258	combining data from these arrays into one sample was justified before proceeding with the main
259	analysis (see Supplementary Methods and Supplementary Figures 2 and 3).

260 Network analysis

261 *Estimation*

Network analysis was conducted using *R* software (version 4.0.3; R Core Team, 2017). In
 network analysis, unique associations between variables reflect partial correlations and are

termed 'edges'. Variables in the network are referred to as 'nodes'.

Network models can be broadly categorised into regularized and unregularized models, that have
 distinct advantages and disadvantages. Regularised models apply penalties that shrink edges

towards zero. This has the advantage that it results in sparser and more parsimonious network

268 models as small edges can be set exactly to zero. Contrary to this, non-regularized models do not

apply such a penalty while still controlling the false positive rate and recent studies have

270 suggested that unregularized models perform better in estimating psychological symptom

271 networks and multi-plane immunopsychiatric networks than regularized network models

272 (Moriarity et al., 2020a; Williams et al., 2019). A disadvantage of unregularized models,

273 however, is that they are currently only suitable for network estimation of individual

samples/datasets. Contrary to this, regularised models have recently been adapted for application

in multi-sample contexts using so-called fused graphical LASSO (FGL) estimation. FGL

estimation allows synthesising data across multiple samples, which increases statistical power.

Based on these respective advantages and disadvantages, we have decided to use a regularized network model as primary analysis, which maximises statistical power due to the multi-sample design of our study. As unregularized models are preferable for estimation of individual samples and may be better suited to retrieve multi-plane edges, however, we also apply unregularized network estimation as secondary analysis.

In primary analyses, networks were estimated using FGL estimation as implemented in the
 EstimateGroupNetwork package (version 0.2.2; Costantini et al., 2020, 2019; Danaher et al.,

284 2014). FGL estimation relies on the two tuning parameters λ_1 , which penalizes network density, 285 and λ_2 , which penalizes edge differences across samples. Values for these tuning parameters were 286 selected using 10-fold cross-validation to optimise the Bayesian Information Criterion (BIC). As 287 recommended, we set weights for the importance of each sample as 'equal' to ascertain that a 288 single sample would not dominate estimation (Danaher et al., 2014). 289 As secondary analysis, we estimated unregularized networks for each sample individually using

290 the gaussian graphical stepwise model selection ("ggModSelect") algorithm implemented in the

291 *qgraph* package (version 1.6.5; Epskamp et al., 2012) based on Spearman correlations and

starting from an empty model. Throughout results, we refer to this estimation strategy as

293 "unregularized model search" or "model search" for simplification.

294 *Node predictability*

295 We also estimated node predictability, which describes the amount of variance in a node that is explained by all other nodes in the network, so can be interpreted akin to R^2 (Haslbeck and Fried, 296 297 2017). Node predictability cannot be inferred from FGL or model search networks as it requires a 298 node-wise estimation approach. Therefore, we used a mixed graphical model as a third estimation 299 strategy as implemented in the mgm package (version 1.2-10), selecting tuning parameter λ based 300 on BIC optimisation in 10-fold cross-validation (Haslbeck and Waldorp, 2020). Of note, this 301 model was only used to infer node predictability, which provides additional information on 302 network density and sample comparability. However, we do not report any individual edge 303 estimates based on this model as FGL estimation and unregularized model search are better 304 suited for our study aims.

305 Visualisation

Networks were visualised with the *qgraph* package using an average layout estimated with the Fruchterman-Reingold algorithm for the FGL networks. This algorithm places nodes close to each other that are connected by large edges (Epskamp et al., 2012). While this simplifies network appraisal, it is important to note that nodes and edges should not be interpreted based on their relative position within the network, which can be unstable.

311 Stability

312 To evaluate stability of estimated networks, we assessed accuracy of edge estimates using

bootstrapping strategies. Specifically, for FGL networks 500 bootstrapped samples with

314 replacement were drawn, and FGL networks re-estimated, using the implementation in the

315 *EstimateGroupNetwork* package (Costantini et al., 2020). For unregularized model search

316 estimation, the same procedure was applied using non-parametric bootstrapping procedures

317 implemented in the *bootnet* package (version 1.4.3; Epskamp et al., 2018).

318 Interpretation

319 We interpreted estimated networks based on the presence, stability, and replicability of edges as 320 defined using three consistency criteria. First, we tested if edges were nonzero in FGL networks 321 as well as nonzero and directionally consistent in >50% of bootstrapped analyses (consistency 322 criterion 1) akin to a previous PRS-symptom network study in psychosis by Isvoranu and 323 colleagues (2020). Second, we tested if edges between PRSs and symptoms replicated (according 324 to criterion 1) across FGL networks of the three samples (consistency criterion 2). Third, we 325 tested if edges were present in secondary analyses using unregularized model search estimation, 326 again confirmed in >50% of bootstrapped estimations exhibiting directionally consistent 327 estimates (consistency criterion 3).

328 Availability of data and materials

- 329 Data from original studies is not openly available, but can be requested; see details in
- 330 Supplementary Table 7. GWAS summary data for IL-6, IL-10, and TNF-α is openly available
- from the original publication by Ahola-Olli and colleagues (2017), for BMI from the GIANT
- consortium, and can be requested for CRP from the CHARGE inflammation working group. We
- 333 provide analysis scripts and estimated network matrices (including bootstrapped network
- matrices) on the Open Science Platform (OSF) under https://osf.io/q4vw9/.

335 **RESULTS**

Baseline characteristics of study populations are displayed in Table 1.

337 -Table 1-

338 Network analysis

- 339 We conducted network analyses of five immuno-metabolic PRSs (CRP, IL-6, IL-10, TNF-α, &
- 340 BMI) and seven depressive symptoms using two estimation techniques (FGL & unregularized
- 341 model search estimation) in three samples (MARS, STAR*D & UK Biobank). Bootstrap
- analyses were conducted to assess stability of networks and node predictability estimated using a
- 343 mixed graphical model. We defined three consistency criteria to assess robustness and
- 344 replicability of our results across estimation techniques, bootstrapping, and samples. Focus of this
- 345 network investigation were unique associations (termed edges in network analysis) between PRSs
- and symptoms, which are summarised in Table 2.

Fused Graphical LASSO (FGL) estimation suggests four consistent PRS-symptom edges according to criteria 1 & 2

- 349 Using FGL estimation, we obtained networks that are visualised in Figure 2. PRS-symptom edge
- 350 bootstrapping results are displayed in Figure 3 with PRS-PRS and symptom-symptom edge
- bootstrapping results shown in Supplementary Figures 4 and 5.
- 352 As expected, nodes within the same plane displayed relatively stronger within-plane (i.e.,
- 353 symptom-symptom & PRS-PRS) than between-plane (i.e., PRS-symptom) associations. Among
- 354 PRSs, CRP displayed associations with BMI (edge weight range across samples: 0.16-0.19) while
- 355 IL-6, IL-10, and TNF- α (based on the same GWAS) were associated with each other (edge
- 356 weight range across samples: 0.08-0.52). Associations of BMI and CRP with IL-6, IL-10, and
- TNF-α were largely absent or very small (edge weight range across samples: -0.02-0.01). Among

358	symptoms, the largest associations were present between the core symptoms depressed mood and
359	anhedonia (edge weight range across samples: 0.14-0.55), which is to-be-expected in clinical
360	samples where these symptoms form the basis of the MDD diagnosis. Supplementary Figure 4
361	also illustrates interesting edge differences between samples that are likely arising from the
362	diverging symptom definitions in individual samples. For instance, edges of fatigue with changes
363	in appetite (edge weight=0.21) and sleep problems (edge weight=0.33) were relatively larger in
364	the UK Biobank, assessing composite symptoms of changes in appetite and sleep problems, but
365	substantially smaller in MARS (fatigue-changes in appetite: edge weight=0.09; fatigue-sleep
366	problems: edge weight=0.10) and STAR*D (fatigue-changes in appetite: edge weight=-0.01;
367	fatigue-sleep problems: edge weight=-0.01), assessing loss of appetite and insomnia.
368	Regarding PRS-symptom edges, FGL estimation surprisingly resulted in a much larger number of
369	PRS-symptom edges in MARS and STAR*D samples compared to the UK Biobank sample with
370	28 (MARS), 29 (STAR*D), and 6 (UK Biobank) nonzero PRS-symptom edges. 26 (MARS), 28
371	(STAR*D), and 5 (UK Biobank) of these edges fulfilled criterion 1 (nonzero edges are nonzero
372	and directionally consistent in >50% of bootstraps). Although the difference between samples
373	could have resulted from network differences of clinical versus general population-based
374	samples, it may also reflect some degree of inconsistency or even noise as edge estimates often
375	exhibited unstable directions of association in clinical samples (see Table 2).
376	Applying consistency criterion 2 (consistency of results across samples), we observed replicable
377	edges of the CRP PRS with anhedonia (negative edge weight), changes in appetite, and fatigue
378	and of the TNF- α PRS with fatigue; these edges were manually unfaded in Figure 2. It is
379	important to note that the edge between the CRP PRS and changes in appetite has a diverging
380	valence in individual samples; in MARS and STAR*D (assessing loss of appetite) the edge

381 weight was negative and in the UK Biobank study (assessing changes in appetite) the edge

382 weight was positive.

383 -Figure 2-

384 -Figure 3-

Unregularized model search estimation suggests three consistent PRS-symptom edges according to criterion 3.

387 Using unregularized model search estimation, we again observed networks with relatively larger

388 within-plane (i.e., PRS-PRS & symptom-symptom) than between-plane (i.e., PRS-symptom)

389 edges. Networks were comparable to FGL estimation, but generally sparser than those using FGL

390 estimation; see network graphs in Supplementary Figure 6 and bootstrapping results in

391 Supplementary Figures 7-9.

392 Regarding PRS-symptom edges, only three edges were estimated, which were all observed in the

393 UK Biobank sample and fulfilled consistency criterion 3 (nonzero edges are also nonzero and

directionally consistent in >50% of bootstraps); these edges have been manually unfaded in

395 Supplementary Figure 6. The specific PRS-symptom edges were between the BMI PRS and

396 changes in appetite and anhedonia and between the CRP PRS and changes in appetite.

397 Comparing these edges to FGL estimation, the edge of the CRP PRS with changes in appetite

398 replicated one of the edges fulfilling consistency criteria 1 and 2 while the two edges observed

399 for the BMI PRS were only fulfilling consistency criterion 1 (presence in FGL estimation and

400 >50% of bootstraps). Moreover, the BMI PRS association with anhedonia was negative using

401 unregularized model search estimation, but positive using FGL estimation.

402

-Table 2-

403 Node predictability

- 404 Average node predictability was similar across samples for PRS nodes with 16% (UK Biobank),
- 405 17% (MARS), and 19% (STAR*D) of variance explained by all other nodes in the network.
- 406 Contrary to this, average node predictability for symptom nodes differed with 38% of variance
- 407 explained by all other nodes in the UK Biobank sample and only 9% in both clinical samples.
- 408 These findings highlight differences in network density of symptoms in the UK Biobank (using
- 409 the PHQ-9) and clinical samples (using the HAM-D).

410 **DISCUSSION**

411 The present study investigated associations of PRSs for immuno-metabolic markers with 412 depressive symptoms using a multi-plane, multi-sample network analysis approach. Based on 413 three consistency criteria emphasising robustness and replicability of network analysis results 414 across statistical bootstraps, samples, and estimation methods, we observed a unique association 415 between the CRP PRS and changes in appetite that met all three consistency criteria. In addition 416 to this association, we observed five additional PRS-symptom associations that met two 417 consistency criteria. These included edges of the CRP PRS with anhedonia (negative association) 418 and fatigue, the TNF- α PRS with fatigue, and the BMI PRS with anhedonia and changes in 419 appetite. However, the BMI PRS-anhedonia association switched association direction depending 420 on the estimation method, so may not be fully consistent despite fulfilling our consistency 421 criteria. Due to the novelty of our analysis approach, we highlight several methodological 422 considerations below, which we hope provides a helpful framework to the discussion of our 423 findings afterwards.

424 Methodological challenges and opportunities

425 Combining PRSs with psychological symptom networks is a relatively recent extension of 426 network analysis and, to our knowledge, has only been applied in one previous investigation 427 incorporating a schizophrenia PRS into a psychotic symptom network (Isvoranu et al., 2020). 428 Therefore, it is important to emphasise the unique challenges and opportunities of this approach. 429 First, as noted by Isvoranu and colleagues (2020), statistical power is potentially the greatest 430 challenge of PRS-symptom network analysis. Network analysis itself requires relatively large 431 sample sizes for psychological symptom networks (Epskamp et al., 2018; Fried and Cramer, 432 2017), which should be in the hundreds or thousands depending on the number of nodes in the

network. Inclusion of PRSs into psychological symptom networks, and especially of potential
pathomechanistic (e.g., inflammatory) rather than main illness (e.g., depression/schizophrenia)
scores into these networks, aggravates the sample size requirements for network analysis as PRSs
only explain a fraction of variance in the heritable component of their target phenotypes (Choi et
al., 2020; Wray et al., 2020).

438 Second, and because PRSs only measure a fraction of variance in their target phenotype, unique 439 associations observed in network analyses are inevitably smaller than actual target phenotype-440 symptom associations. Taking this study as an example, absolute sizes of CRP PRS-symptom 441 associations were 5- to 10-fold smaller than those from a prior network investigation using serum 442 CRP concentrations by Moriarity and colleagues (2020a). Therefore, PRS-symptom associations 443 are unlikely to give meaningful insights into size of association with the target phenotype, but 444 should, in our opinion, be interpreted based on robust presence/absence of specific associations. 445 Third, the large statistical power requirements and difficulty quantifying such power for a given 446 study may lead to biased result interpretations. Absence of PRS-symptom associations could be 447 interpreted as false negatives while presence of association may be interpreted as true positives. 448 Such divergence in interpretation necessarily biases the literature towards hypothesis 449 confirmation. Consequently, any associations observed in PRS-symptom network analyses 450 should be followed up by- and interpreted in line with- evidence from other studies, thus adhering 451 to the recommended triangulation of evidence approach (Lawlor et al., 2017; Ohlsson and Kendler, 2019). 452

Despite these challenges, PRS-symptom networks also provide multiple opportunities. First,
PRSs reflect estimates of genetic liability to phenotype expression, so can give an indication on
the influence of lifelong predisposition to higher phenotype levels on the symptom level. In this

456 way, PRS-symptom associations also provide an indication regarding temporality of association, 457 which Bradford-Hill defined as one of the viewpoints for causality (Bradford Hill, 1965). It is 458 important to note, however, that evidence for a unidirectional temporal association does not 459 preclude bi-directionality. Moreover, PRSs combine information from a multitude of genetic 460 variants (in our case from ~1 million SNPs) that are not restricted to functional SNPs, can include 461 false positive associations (i.e., noise), and can also tag information of pleiotropic environmental 462 confounding factors. Therefore, causal inferences should rely on separate evidence from clinical 463 trials and/or more focused genetic approaches such as Mendelian Randomisation studies (Lawlor 464 et al., 2008).

Second, the PRS-symptom network analysis approach allows the concurrent investigation of multiple immuno-metabolic markers with multiple symptoms. Thereby, immunological and clinical complexity is addressed concurrently, which is an advantage to previous investigations. Furthermore, network analyses usually estimate partial/unique associations, so any emerging associations could suggest direct causal paths from PRS phenotypes to individual symptoms, so may pinpoint so-called 'bridge symptoms' that act as etiological docking sites of risk effects on the symptom plane.

Third, large-scale population-based or patient cohort studies, commonly used in network
analysis, often do not have detailed immunophenotyping data available. If at all, studies mostly
have data available for serum CRP, but rarely for more specific cytokines. Conversely, the advent
of large GWAS investigations has produced a substantial amount of large cohort databases with
in-depth genotyping and phenotyping information. Combining such databases with GWAS
summary statistics from more focused investigations, such as on individual cytokines (Ahola-Olli

et al., 2017), enables the investigation of a diverse range of immunopsychiatric researchquestions.

Fourth, PRS-symptom networks could be extended, for instance, by adding serum inflammatory
markers to these networks, which could provide additional insights into associations between
genetic/lifelong predisposition to, and acute levels of, immuno-metabolic markers with individual
symptoms.

484 Associations of immuno-metabolic markers with depressive symptoms

485 Network analysis results showed consistent associations of the CRP PRS with changes in

486 appetite, which was the only association that fulfilled all of our quality criteria. The BMI PRS

487 showed similar associations with changes in appetite, but only fulfilled two quality criteria.

488 Importantly, both of these associations were positive in the UK Biobank sample, which assessed

489 changes in appetite, and negative in MARS and STAR*D samples, which assessed loss of

490 appetite. Previous studies reporting results from cross-sectional, longitudinal, genetic correlation,

491 PRS, and Mendelian randomisation analyses have also consistently reported associations of

492 CRP/BMI with changes in appetite (Fried et al., 2019; Jokela et al., 2016; Kappelmann et al.,

493 2021; Moriarity et al., 2020a). Importantly, whenever studies disaggregated appetite symptoms

494 into decreased versus increased appetite, associations of CRP/BMI were specific to increased

495 appetite (Lamers et al., 2018; Milaneschi et al., 2021b, 2021a, 2017b; Pistis et al., 2021;

496 Simmons et al., 2018). In light of these findings, our results provide indirect support for an

497 immune-metabolic contribution to increased appetite specifically.

498 In addition to these PRS associations with changes in appetite, we also observed associations of

499 higher CRP PRS with lower anhedonia and greater fatigue and of higher TNF-α PRS with greater

500 fatigue. Fatigue in particular has long been considered to have a neuroimmune basis (Dantzer et

501 al., 2014), is common across other medical illnesses characterised by chronic inflammation, and 502 has been reliably associated with inflammatory markers in previous studies including two 503 network investigations (Fried et al., 2019; Jokela et al., 2016; Lamers et al., 2020; Moriarity et 504 al., 2020a; van Eeden et al., 2020; White et al., 2017). While there have also been some studies 505 suggesting associations of inflammatory markers with anhedonia (Köhler-Forsberg et al., 2017; 506 van Eeden et al., 2020), it is important to note that associations of the CRP PRS with anhedonia 507 observed in the present report were negative, so do not offer straightforward replication of these 508 findings. Nonetheless, we have recently shown in Mendelian randomisation analyses that BMI 509 could be a potential causal factor for both fatigue and anhedonia (Kappelmann et al., 2021), so 510 continued investigation of these symptoms is warranted. 511 Together, our findings add to the notion of an immuno-metabolic subtype of depression 512 characterised by neurovegetative symptoms of changes in appetite and fatigue (Dantzer et al., 513 2008; Milaneschi et al., 2020). We also expand upon previous work by showing that 514 genetic/lifetime predisposition to higher inflammation and metabolic dysregulation increases risk 515 for depression and, based on network analysis results, these etiological factors may specifically 516 confer their risk on the broader depression syndrome through symptoms such as changes in 517 appetite and fatigue. These results can inform the design of clinical trials of anti-inflammatory 518 approaches and metabolic interventions by specifically selecting patients with an atypical, 519 neurovegetative symptom presentation. As clinical trials for immune-modulating drugs are 520 currently still characterised by relatively small sample sizes (Husain et al., 2020; Khandaker et 521 al., 2018; McIntyre et al., 2019; Nettis et al., 2021; Raison et al., 2013), it may be worthwhile to 522 pilot new interventions with neurovegetative symptoms/phenotypes as outcome variables. This 523 might increase statistical power and sensitivity to detect effects for these proof-of-concept trials 524 and could then be followed up by larger trials testing broader clinical efficacy measures.

525 Strengths and limitations

526 Strength of this study include availability of large general population-based and patient samples 527 (maximising replicability and generalisability), polygenic definition of immuno-metabolic risk 528 variables (indexing lifetime predisposition to higher immuno-metabolic marker levels), and 529 application of network analysis (addressing immunological and clinical complexity 530 concurrently). We have addressed some of the more general limitations of combined PRS-531 symptom network analysis above, but there are three more specific limitations that warrant 532 mentioning.

533 First, data used in the current study included inpatients, outpatients, and individuals from the

534 general population and was based on different scales to measure depressive symptoms.

535 Depressive symptom structure varies between acutely ill patients versus those in remission (van

536 Borkulo et al., 2015), which may have influenced PRS-symptom associations. Moreover, two of

the seven symptoms used in the present report only overlap partially; the UK Biobank study

538 includes conflated items on sleep problems and changes in appetite while MARS and STAR*D

539 include items on insomnia and loss of appetite, respectively. This difference may explain some of

540 the inconsistencies observed in the current report such as the diverging valence of edge estimates

541 between CRP and changes in appetite. However, this may have also reduced statistical power to

542 detect associations. Study questionnaires also differed regarding the method of assessment as the

543 HAM-D is observer-rated and the PHQ-9 self-reported. By definition, inflammation-symptom

research is affected from modality-specific measurement variability (Moriarity and Alloy, 2021)

and in our study this is aggravated through the added variability unique to the method of

546 symptom assessment (Möller, 2000). Future studies would benefit from inclusion of studies with

547 the same questionnaire and disaggregated symptom measures.

548	Second, the combination of clinical and general population samples poses unique challenges. The
549	application of a clinical depression measure in the UK Biobank study could have resulted in
550	potential floor effects for some symptoms while specific selection of MDD patients into MARS
551	and STAR*D studies could have resulted in ceiling effects for core symptoms of depressed mood
552	and anhedonia as these are required for a diagnosis. Selection of clinical populations in network
553	studies can also result in Berkson/collider bias (de Ron et al., 2019), which can induce negative
554	correlations. This again warrants replication of our results in independent samples.
555	Third, PRSs are based on GWAS with highly diverging samples sizes as a large number of
556	individuals were included in the GWAS for BMI and CRP (>200 thousand individuals) and
557	smaller numbers of individuals (~8 thousand individuals) for IL-6, IL-10, and TNF- α .
558	Consistency of effect sizes following the PRS-CS approach was also larger for CRP and BMI as
559	compared to IL-6, IL-10, and TNF- α . This is likely to have shifted the balance of statistical
560	power towards detection of PRS-symptom associations to BMI and CRP rather than IL-6, IL-10,
561	and TNF- α . Therefore, our findings require replication once larger individual cytokine GWAS
562	become available.

563 Conclusion

The present investigation studied associations between four major pro- and anti-inflammatory markers, BMI, and depressive symptoms by applying network analysis across one large general population and two patient samples. Defining immuno-metabolic markers using polygenic risk scores expanded previous reports by suggesting direct associations of genetic/lifetime predisposition to immune-metabolic markers with depressive symptoms and provided evidence for temporality of association. Despite methodological restrictions of the presented approach, we observed associations of polygenic risk for CRP with changes in appetite and fatigue, for TNF- α

- 571 with fatigue, and similar associations for BMI. These findings align with recent
- 572 conceptualisations of an immuno-metabolic subgroup of depressed patients characterised by
- 573 atypical, neurovegetative symptom profiles. Results can inform future clinical trials of anti-
- 574 inflammatory approaches by prioritising these patients for selection into clinical trials.

DECLARATION OF INTERESTS

The authors do not have any competing interests.

FUNDING

This study is funded by the Max Planck Institute of Psychiatry. NK, NR, and SM are supported by the International Max Planck Research School of Translational Psychiatry (IMPRS-TP). NR received funding from the Bavarian Ministry of Economic Affairs, Regional Development and Energy (BayMED, PBN_MED-1711-0003). GMK acknowledges funding support from the Wellcome Trust (grant code: 201486/Z/16/Z), the MQ: Transforming Mental Health (grant code: MQDS17/40), the Medical Research Council, UK (grant code: MC_PC_17213 and grant code: MR/S037675/1), and the BMA Foundation (J Moulton grant 2019). JA received support by a NARSAD Young Investigator Grant from Brain and Behavior Research Foundation.

ACKNOWLEDGMENTS

We are grateful to all original authors, technical assistants and patients who contributed to the MARS study. We are grateful for the National Institute of Mental Health (NIMH) and the NIMH Repository and Genomics Resource (NRGR) for the possibility of analysing the STAR*D data. We are also grateful to the original STAR*D authors, and particularly for the contributions of all patients and families who participated in the study. Data were obtained from the limited access datasets distributed from the NIH-supported 'Sequenced Treatment Alternatives to Relieve Depression' (STAR*D). The study was supported by NIMH Contract No. N01MH90003 to the University of Texas Southwestern Medical Center. The ClinicalTrials.gov identifier is NCT00021528. This research has been conducted using the UK Biobank Resource. We are grateful for all scientists and participants who made this large-scale effort and resource possible.

REFERENCES

- Ahola-Olli, A. V, Würtz, P., Havulinna, A.S., Aalto, K., Pitkänen, N., Lehtimäki, T., Kähönen, M., Lyytikäinen, L.-P., Raitoharju, E., Seppälä, I., Sarin, A.-P., Ripatti, S., Jalkanen, S., Maksimow, M., Salomaa, V., Salmi, M., Kettunen, J., Raitakari, O.T., 2017. Genome-wide Association Study Identifies 27 Loci Influencing Concentrations of Circulating Cytokines and Growth Factors. Am. J. Hum. Genet. 100, 40–50. https://doi.org/10.1016/j.ajhg.2016.11.007
- Badini, I., Coleman, J.R., Hagenaars, S.P., Hotopf, M., Breen, G., Lewis, C.M., Fabbri, C., 2020.
 Depression with atypical neurovegetative symptoms shares genetic predisposition with immuno-metabolic traits and alcohol consumption. Psychol. Med. 1–11.
 https://doi.org/10.1017/S0033291720002342
- Bilder, R.M., Volavka, J., Lachman, H.M., Grace, A.A., 2004. The Catechol-O-Methyltransferase Polymorphism: Relations to the Tonic–Phasic Dopamine Hypothesis and Neuropsychiatric Phenotypes. Neuropsychopharmacology 29, 1943–1961. https://doi.org/10.1038/sj.npp.1300542
- Borsboom, D., 2017. A network theory of mental disorders. World Psychiatry 16, 5–13. https://doi.org/10.1002/wps.20375
- Bradford Hill, A., 1965. The environment and disease: association or causation? Proc. R. Soc. Med. 58, 295.
- Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A., Vukcevic,D., Delaneau, O., O'Connell, J., Cortes, A., Welsh, S., Young, A., Effingham, M., McVean,G., Leslie, S., Allen, N., Donnelly, P., Marchini, J., 2018. The UK Biobank resource with

deep phenotyping and genomic data. Nature 562, 203–209. https://doi.org/10.1038/s41586-018-0579-z

- Cattaneo, A., Ferrari, C., Turner, L., Mariani, N., Enache, D., Hastings, C., Kose, M., Lombardo, G., McLaughlin, A.P., Nettis, M.A., Nikkheslat, N., Sforzini, L., Worrell, C., Zajkowska, Z., Cattane, N., Lopizzo, N., Mazzelli, M., Pointon, L., Cowen, P.J., Cavanagh, J., Harrison, N.A., de Boer, P., Jones, D., Drevets, W.C., Mondelli, V., Bullmore, E.T., Pariante, C.M., 2020. Whole-blood expression of inflammasome- and glucocorticoid-related mRNAs correctly separates treatment-resistant depressed patients from drug-free and responsive patients in the BIODEP study. Transl. Psychiatry 10, 232. https://doi.org/10.1038/s41398-020-00874-7
- Choi, S.W., Mak, T.S.-H., O'Reilly, P.F., 2020. Tutorial: a guide to performing polygenic risk score analyses. Nat. Protoc. 15, 2759–2772. https://doi.org/10.1038/s41596-020-0353-1
- Chu, A.L., Stochl, J., Lewis, G., Zammit, S., Jones, P.B., Khandaker, G.M., 2019. Longitudinal association between inflammatory markers and specific symptoms of depression in a prospective birth cohort. Brain. Behav. Immun. 76, 74–81. https://doi.org/10.1016/j.bbi.2018.11.007
- Contreras, A., Nieto, I., Valiente, C., Espinosa, R., Vazquez, C., 2019. The Study of Psychopathology from the Network Analysis Perspective: A Systematic Review.
 Psychother. Psychosom. 88, 71–83. https://doi.org/10.1159/000497425
- Costantini, G., Kappelmann, N., Epskamp, S., 2020. EstimateGroupNetwork: Perform the Joint Graphical Lasso and Selects Tuning Parameters.
- Costantini, G., Richetin, J., Preti, E., Casini, E., Epskamp, S., Perugini, M., 2019. Stability and

variability of personality networks. A tutorial on recent developments in network psychometrics. Pers. Individ. Dif. 136, 68–78. https://doi.org/10.1016/j.paid.2017.06.011

- Danaher, P., Wang, P., Witten, D.M., 2014. The joint graphical lasso for inverse covariance estimation across multiple classes. J. R. Stat. Soc. Ser. B (Statistical Methodol. 76, 373–397. https://doi.org/10.1111/rssb.12033
- Dantzer, R., Heijnen, C.J., Kavelaars, A., Laye, S., Capuron, L., 2014. The neuroimmune basis of fatigue. Trends Neurosci. 37, 39–46. https://doi.org/10.1016/j.tins.2013.10.003
- Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., 2008. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9, 46–56. https://doi.org/10.1038/nrn2297
- Davis, K.A.S., Coleman, J.R.I., Adams, M., Allen, N., Breen, G., Cullen, B., Dickens, C., Fox,
 E., Graham, N., Holliday, J., Howard, L.M., John, A., Lee, W., McCabe, R., McIntosh, A.,
 Pearsall, R., Smith, D.J., Sudlow, C., Ward, J., Zammit, S., Hotopf, M., 2020. Mental health
 in UK Biobank development, implementation and results from an online questionnaire
 completed by 157 366 participants: a reanalysis. BJPsych Open 6, e18.
 https://doi.org/10.1192/bjo.2019.100
- de Ron, J., Fried, E.I., Epskamp, S., 2019. Psychological networks in clinical populations: investigating the consequences of Berkson's bias. Psychol. Med. 1–9. https://doi.org/10.1017/S0033291719003209
- Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lanctôt, K.L., 2010. A Meta-Analysis of Cytokines in Major Depression. Biol. Psychiatry 67, 446–457. https://doi.org/10.1016/j.biopsych.2009.09.033

- Epskamp, S., Borsboom, D., Fried, E.I., 2018. Estimating psychological networks and their accuracy: A tutorial paper. Behav. Res. Methods 50, 195–212. https://doi.org/10.3758/s13428-017-0862-1
- Epskamp, S., Cramer, A.O.J., Waldorp, L.J., Schmittmann, V.D., Borsboom, D., 2012. qgraph□: Network Visualizations of Relationships in Psychometric Data. J. Stat. Softw. 48, 1–18. https://doi.org/10.18637/jss.v048.i04
- Fried, E.I., Cramer, A.O.J., 2017. Moving forward: Challenges and direction for psychopathological network theory and methodology. Perspect. Psychol. Sci. 12, 999–1020. https://doi.org/10.1177/1745691617705892
- Fried, E.I., von Stockert, S., Haslbeck, J.M.B., Lamers, F., Schoevers, R.A., Penninx, B.W.J.H., 2019. Using network analysis to examine links between individual depressive symptoms, inflammatory markers, and covariates. Psychol. Med. 1–9. https://doi.org/10.1017/S0033291719002770
- Garriock, H.A., Kraft, J.B., Shyn, S.I., Peters, E.J., Yokoyama, J.S., Jenkins, G.D., Reinalda, M.S., Slager, S.L., McGrath, P.J., Hamilton, S.P., 2010. A Genomewide Association Study of Citalopram Response in Major Depressive Disorder. Biol. Psychiatry 67, 133–138. https://doi.org/10.1016/j.biopsych.2009.08.029
- Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C.A., Smoller, J.W., 2019. Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat. Commun. 10, 1776. https://doi.org/10.1038/s41467-019-09718-5
- Goldsmith, D.R., Rapaport, M.H., Miller, B.J., 2016. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and

depression. Mol. Psychiatry 21, 1696–1709. https://doi.org/10.1038/mp.2016.3

- Guloksuz, S., Pries, L.-K., van Os, J., 2017. Application of network methods for understanding mental disorders: pitfalls and promise. Psychol. Med. 47, 2743–2752. https://doi.org/10.1017/S0033291717001350
- Haapakoski, R., Mathieu, J., Ebmeier, K.P., Alenius, H., Kivimäki, M., 2015. Cumulative metaanalysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain. Behav. Immun. 49, 206–215. https://doi.org/10.1016/j.bbi.2015.06.001
- Hamilton, M., 1986. The Hamilton Rating Scale for Depression, in: Sartorius, N., Ban, T.A.
 (Eds.), Assessment of Depression. Springer Berlin Heidelberg, Berlin, Heidelberg, pp. 143– 152. https://doi.org/10.1007/978-3-642-70486-4_14
- Haslbeck, J.M.B., Fried, E.I., 2017. How predictable are symptoms in psychopathological networks? A reanalysis of 18 published datasets. Psychol. Med. 47, 2767–2776. https://doi.org/10.1017/S0033291717001258
- Haslbeck, J.M.B., Waldorp, L.J., 2020. mgm : Estimating Time-Varying Mixed Graphical Models in High-Dimensional Data. J. Stat. Softw. 93. https://doi.org/10.18637/jss.v093.i08
- Hennings, J.M., Owashi, T., Binder, E.B., Horstmann, S., Menke, A., Kloiber, S., Dose, T.,
 Wollweber, B., Spieler, D., Messer, T., Lutz, R., Kü Nzel, H., Bierner, T., Pollmächer, T.,
 Pfister, H., Nickel, T., Sonntag, A., Uhr, M., Ising, M., Holsboer, F., Lucae, S., 2009.
 Clinical characteristics and treatment outcome in a representative sample of depressed
 inpatients Findings from the Munich Antidepressant Response Signature (MARS) project.
 J. Psychiatr. Res. 43, 215–229. https://doi.org/10.1016/j.jpsychires.2008.05.002

- Howren, M.B., Lamkin, D.M., Suls, J., 2009. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 71, 171–186. https://doi.org/10.1097/PSY.0b013e3181907c1b
- Husain, M.I., Chaudhry, I.B., Khoso, A.B., Husain, M.O., Hodsoll, J., Ansari, M.A., Naqvi, H.A., Minhas, F.A., Carvalho, A.F., Meyer, J.H., Deakin, B., Mulsant, B.H., Husain, N., Young, A.H., 2020. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. The Lancet Psychiatry 7, 515–527. https://doi.org/10.1016/S2215-0366(20)30138-3
- Isvoranu, A.-M., Guloksuz, S., Epskamp, S., van Os, J., Borsboom, D., 2020. Toward incorporating genetic risk scores into symptom networks of psychosis. Psychol. Med. 50, 636–643. https://doi.org/10.1017/S003329171900045X
- Jokela, M., Virtanen, M., Batty, G., Kivimäki, M., 2016. Inflammation and specific symptoms of depression. JAMA Psychiatry 73, 87–88. https://doi.org/10.1001/jamapsychiatry.2015.1977
- Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms. JAMA Psychiatry 78, 161–170. https://doi.org/10.1001/jamapsychiatry.2020.3436
- Kappelmann, N., Lewis, G., Dantzer, R., Jones, P.B., Khandaker, G.M., 2018. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol. Psychiatry 23, 335–343. https://doi.org/10.1038/mp.2016.167

Khandaker, G.M., Oltean, B.P., Kaser, M., Dibben, C.R.M., Ramana, R., Jadon, D.R., Dantzer,

R., Coles, A.J., Lewis, G., Jones, P.B., 2018. Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation. BMJ Open 8, e025333. https://doi.org/10.1136/bmjopen-2018-025333

- Khandaker, G.M., Pearson, R.M., Zammit, S., Lewis, G., Jones, P.B., 2014. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry 71, 1121–1128. https://doi.org/10.1001/jamapsychiatry.2014.1332
- Köhler-Forsberg, O., Buttenschøn, H.N., Tansey, K.E., Maier, W., Hauser, J., Dernovsek, M.Z., Henigsberg, N., Souery, D., Farmer, A., Rietschel, M., McGuffin, P., Aitchison, K.J., Uher, R., Mors, O., 2017. Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression. Brain. Behav. Immun. 62, 344–350. https://doi.org/10.1016/j.bbi.2017.02.020
- Köhler-Forsberg, O., Nicolaisen Lydholm, C., Hjorthøj, C., Nordentoft, M., Mors, O., Benros, M.E., 2019. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: Meta-analysis of clinical trials. Acta Psychiatr. Scand. 0–2. https://doi.org/10.1111/acps.13016
- Köhler, C.A., Freitas, T.H., Maes, M., de Andrade, N.Q., Liu, C.S., Fernandes, B.S., Stubbs, B., Solmi, M., Veronese, N., Herrmann, N., Raison, C.L., Miller, B.J., Lanctôt, K.L., Carvalho, A.F., 2017. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr. Scand. 135, 373–387. https://doi.org/10.1111/acps.12698
- Lamers, F., Milaneschi, Y., de Jonge, P., Giltay, E.J., Penninx, B.W.J.H., 2018. Metabolic and inflammatory markers: associations with individual depressive symptoms. Psychol. Med. 48,

1102-1110. https://doi.org/10.1017/S0033291717002483

- Lamers, F., Milaneschi, Y., Smit, J.H., Schoevers, R.A., Wittenberg, G., Penninx, B.W.J.H., 2019. Longitudinal Association Between Depression and Inflammatory Markers: Results From the Netherlands Study of Depression and Anxiety. Biol. Psychiatry 85, 829–837. https://doi.org/10.1016/j.biopsych.2018.12.020
- Lamers, F., Milaneschi, Y., Vinkers, C.H., Schoevers, R.A., Giltay, E.J., Penninx, B.W.J.H.,
 2020. Depression profilers and immuno-metabolic dysregulation: Longitudinal results from the NESDA study. Brain. Behav. Immun. 88, 174–183.
 https://doi.org/10.1016/j.bbi.2020.04.002
- Lamnidis, T.C., Majander, K., Jeong, C., Salmela, E., Wessman, A., Moiseyev, V., Khartanovich, V., Balanovsky, O., Ongyerth, M., Weihmann, A., Sajantila, A., Kelso, J., Pääbo, S., Onkamo, P., Haak, W., Krause, J., Schiffels, S., 2018. Ancient Fennoscandian genomes reveal origin and spread of Siberian ancestry in Europe. Nat. Commun. 9, 5018. https://doi.org/10.1038/s41467-018-07483-5
- Lawlor, D.A., Harbord, R.M., Sterne, J.A.C., Timpson, N., Davey Smith, G., 2008. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat. Med. 27, 1133–1163. https://doi.org/10.1002/sim.3034
- Lawlor, D.A., Tilling, K., Davey Smith, G., 2017. Triangulation in aetiological epidemiology. Int. J. Epidemiol. 45, dyw314. https://doi.org/10.1093/ije/dyw314
- Ligthart, S., Vaez, A., Võsa, U., Stathopoulou, M.G., de Vries, P.S., Prins, B.P., Van der Most,
 P.J., Tanaka, T., Naderi, E., Rose, L.M., Wu, Y., Karlsson, R., Barbalic, M., Lin, H., Pool,
 R., Zhu, G., Macé, A., Sidore, C., Trompet, S., Mangino, M., Sabater-Lleal, M., Kemp, J.P.,

Abbasi, A., Kacprowski, T., Verweij, N., Smith, A. V, Huang, T., Marzi, C., Feitosa, M.F.,

- Lohman, K.K., Kleber, M.E., Milaneschi, Y., Mueller, C., Huq, M., Vlachopoulou, E.,
- Lyytikäinen, L.-P., Oldmeadow, C., Deelen, J., Perola, M., Zhao, J.H., Feenstra, B., Amini,
- M., Lahti, J., Schraut, K.E., Fornage, M., Suktitipat, B., Chen, W.-M., Li, X., Nutile, T.,
- Malerba, G., Luan, J., Bak, T., Schork, N., Del Greco M., F., Thiering, E., Mahajan, A.,
- Marioni, R.E., Mihailov, E., Eriksson, Joel, Ozel, A.B., Zhang, W., Nethander, M., Cheng,
- Y.-C., Aslibekyan, S., Ang, W., Gandin, I., Yengo, L., Portas, L., Kooperberg, C., Hofer, E.,
- Rajan, K.B., Schurmann, C., den Hollander, W., Ahluwalia, Tarunveer S., Zhao, J.,
- Draisma, H.H.M., Ford, I., Timpson, N., Teumer, A., Huang, H., Wahl, S., Liu, Y., Huang,
- J., Uh, H.-W., Geller, F., Joshi, P.K., Yanek, L.R., Trabetti, E., Lehne, B., Vozzi, D.,
- Verbanck, M., Biino, G., Saba, Y., Meulenbelt, I., O'Connell, J.R., Laakso, M., Giulianini,
- F., Magnusson, P.K.E., Ballantyne, C.M., Hottenga, J.J., Montgomery, G.W., Rivadineira,
- F., Rueedi, R., Steri, M., Herzig, K.-H., Stott, D.J., Menni, C., Frånberg, M., St. Pourcain,
- B., Felix, S.B., Pers, T.H., Bakker, S.J.L., Kraft, P., Peters, A., Vaidya, D., Delgado, G.,
- Smit, J.H., Großmann, V., Sinisalo, J., Seppälä, I., Williams, S.R., Holliday, E.G., Moed,
- M., Langenberg, C., Räikkönen, K., Ding, J., Campbell, H., Sale, M.M., Chen, Y.-D.I.,
- James, A.L., Ruggiero, D., Soranzo, N., Hartman, C.A., Smith, E.N., Berenson, G.S.,
- Fuchsberger, C., Hernandez, D., Tiesler, C.M.T., Giedraitis, V., Liewald, D., Fischer, K.,
- Mellström, D., Larsson, A., Wang, Y., Scott, W.R., Lorentzon, M., Beilby, J., Ryan, K.A.,
- Pennell, C.E., Vuckovic, D., Balkau, B., Concas, M.P., Schmidt, R., Mendes de Leon, C.F.,
- Bottinger, E.P., Kloppenburg, M., Paternoster, L., Boehnke, M., Musk, A.W., Willemsen,
- G., Evans, D.M., Madden, P.A.F., Kähönen, M., Kutalik, Z., Zoledziewska, M., Karhunen,
- V., Kritchevsky, S.B., Sattar, N., Lachance, G., Clarke, R., Harris, T.B., Raitakari, O.T.,
- Attia, J.R., van Heemst, D., Kajantie, E., Sorice, R., Gambaro, G., Scott, R.A., Hicks, A.A.,

Ferrucci, L., Standl, M., Lindgren, C.M., Starr, J.M., Karlsson, M., Lind, L., Li, J.Z.,

- Chambers, J.C., Mori, T.A., de Geus, E.J.C.N., Heath, A.C., Martin, N.G., Auvinen, J.,
- Buckley, B.M., de Craen, A.J.M., Waldenberger, M., Strauch, K., Meitinger, T., Scott, R.J.,
- McEvoy, M., Beekman, M., Bombieri, C., Ridker, P.M., Mohlke, K.L., Pedersen, N.L.,
- Morrison, A.C., Boomsma, D.I., Whitfield, J.B., Strachan, D.P., Hofman, A., Vollenweider,
- P., Cucca, F., Jarvelin, M.-R., Jukema, J.W., Spector, T.D., Hamsten, A., Zeller, T.,
- Uitterlinden, André G., Nauck, M., Gudnason, V., Qi, L., Grallert, H., Borecki, I.B., Rotter,
- J.I., März, W., Wild, P.S., Lokki, M.-L., Boyle, M., Salomaa, V., Melbye, M., Eriksson,
- J.G., Wilson, J.F., Penninx, B.W.J.H., Becker, D.M., Worrall, B.B., Gibson, G., Krauss,
- R.M., Ciullo, M., Zaza, G., Wareham, N.J., Oldehinkel, A.J., Palmer, L.J., Murray, S.S.,
- Pramstaller, P.P., Bandinelli, S., Heinrich, J., Ingelsson, E., Deary, I.J., Mägi, R.,
- Vandenput, L., van der Harst, P., Desch, K.C., Kooner, J.S., Ohlsson, C., Hayward, C.,
- Lehtimäki, T., Shuldiner, A.R., Arnett, D.K., Beilin, L.J., Robino, A., Froguel, P., Pirastu,
- M., Jess, T., Koenig, W., Loos, R.J.F., Evans, D.A., Schmidt, H., Davey Smith, G.,
- Slagboom, P.E., Eiriksdottir, G., Morris, A.P., Psaty, B.M., Tracy, R.P., Nolte, I.M.,
- Boerwinkle, E., Visvikis-Siest, S., Reiner, A.P., Gross, M., Bis, J.C., Franke, L., Franco,
- O.H., Benjamin, E.J., Chasman, D.I., Dupuis, Josée, Snieder, H., Dehghan, A., Alizadeh,
- B.Z., Alizadeh, B.Z., Boezen, H.M., Franke, L., van der Harst, P., Navis, G., Rots, M.,
- Snieder, H., Swertz, M., Wolffenbuttel, B.H.R., Wijmenga, C., Benjamin, E., Chasman,
- D.I., Dehghan, A., Ahluwalia, Tarunveer Singh, Meigs, J., Tracy, R., Alizadeh, B.Z.,
- Ligthart, S., Bis, J., Eiriksdottir, G., Pankratz, N., Gross, M., Rainer, A., Snieder, H.,
- Wilson, J.G., Psaty, B.M., Dupuis, Josee, Prins, B., Vaso, U., Stathopoulou, M., Franke, L.,
- Lehtimaki, T., Koenig, W., Jamshidi, Y., Siest, S., Abbasi, A., Uitterlinden, Andre G.,
- Abdollahi, M., Schnabel, R., Schick, U.M., Nolte, I.M., Kraja, A., Hsu, Y.-H., Tylee, D.S.,

Zwicker, A., Uher, R., Davey Smith, G., Morrison, A.C., Hicks, A., van Duijn, C.M., Ward-Caviness, C., Boerwinkle, E., Rotter, J., Rice, K., Lange, L., Perola, M., de Geus, E., Morris, A.P., Makela, K.M., Stacey, D., Eriksson, Johan, Frayling, T.M., Slagboom, E.P., 2018. Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. Am. J. Hum. Genet. 103, 691–706. https://doi.org/10.1016/j.ajhg.2018.09.009

- Liu, J.J., Wei, Y. Bin, Strawbridge, R., Bao, Y., Chang, S., Shi, L., Que, J., Gadad, B.S., Trivedi, M.H., Kelsoe, J.R., Lu, L., 2020. Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis. Mol. Psychiatry 25, 339–350. https://doi.org/10.1038/s41380-019-0474-5
- Locke, A.E., Kahali, B., Berndt, S.I., Justice, A.E., Pers, T.H., Day, F.R., Powell, C., Vedantam, S., Buchkovich, M.L., Yang, J., Croteau-Chonka, D.C., Esko, T., Fall, T., Ferreira, T., Gustafsson, S., Kutalik, Z., Luan, J., Mägi, R., Randall, J.C., Winkler, T.W., Wood, A.R., Workalemahu, T., Faul, J.D., Smith, J.A., Hua Zhao, J., Zhao, W., Chen, J., Fehrmann, R., Hedman, Å.K., Karjalainen, J., Schmidt, E.M., Absher, D., Amin, N., Anderson, D., Beekman, M., Bolton, J.L., Bragg-Gresham, J.L., Buyske, S., Demirkan, A., Deng, G., Ehret, G.B., Feenstra, B., Feitosa, M.F., Fischer, K., Goel, A., Gong, J., Jackson, A.U., Kanoni, S., Kleber, M.E., Kristiansson, K., Lim, U., Lotay, V., Mangino, M., Mateo Leach, I., Medina-Gomez, C., Medland, S.E., Nalls, M.A., Palmer, C.D., Pasko, D., Pechlivanis, S., Peters, M.J., Prokopenko, I., Shungin, D., Stančáková, A., Strawbridge, R.J., Ju Sung, Y., Tanaka, Toshiko, Teumer, A., Trompet, S., van der Laan, S.W., van Setten, J., Van Vliet-Ostaptchouk, J. V., Wang, Z., Yengo, L., Zhang, W., Isaacs, A., Albrecht, E., Ärnlöv, J., Arscott, G.M., Attwood, A.P., Bandinelli, S., Barrett, A., Bas, I.N., Bellis, C., Bennett, A.J.,

Berne, C., Blagieva, R., Blüher, M., Böhringer, S., Bonnycastle, L.L., Böttcher, Y., Boyd,

- H.A., Bruinenberg, M., Caspersen, I.H., Ida Chen, Y.-D., Clarke, R., Warwick Daw, E., de
- Craen, A.J.M., Delgado, G., Dimitriou, M., Doney, A.S.F., Eklund, N., Estrada, K., Eury,
- E., Folkersen, L., Fraser, R.M., Garcia, M.E., Geller, F., Giedraitis, V., Gigante, B., Go,
- A.S., Golay, A., Goodall, A.H., Gordon, S.D., Gorski, M., Grabe, H.-J., Grallert, H.,
- Grammer, T.B., Gräßler, J., Grönberg, H., Groves, C.J., Gusto, G., Haessler, J., Hall, P.,
- Haller, T., Hallmans, G., Hartman, C.A., Hassinen, M., Hayward, C., Heard-Costa, N.L.,
- Helmer, Q., Hengstenberg, C., Holmen, O., Hottenga, J.-J., James, A.L., Jeff, J.M.,
- Johansson, Å., Jolley, J., Juliusdottir, T., Kinnunen, L., Koenig, W., Koskenvuo, M.,
- Kratzer, W., Laitinen, J., Lamina, C., Leander, K., Lee, N.R., Lichtner, P., Lind, L.,
- Lindström, J., Sin Lo, K., Lobbens, S., Lorbeer, R., Lu, Y., Mach, F., Magnusson, P.K.E.,
- Mahajan, A., McArdle, W.L., McLachlan, S., Menni, C., Merger, S., Mihailov, E., Milani,
- L., Moayyeri, A., Monda, K.L., Morken, M.A., Mulas, A., Müller, G., Müller-Nurasyid, M.,
- Musk, A.W., Nagaraja, R., Nöthen, M.M., Nolte, I.M., Pilz, S., Rayner, N.W., Renstrom, F.,
- Rettig, R., Ried, J.S., Ripke, S., Robertson, N.R., Rose, L.M., Sanna, S., Scharnagl, H.,
- Scholtens, S., Schumacher, F.R., Scott, W.R., Seufferlein, T., Shi, J., Vernon Smith, A.,
- Smolonska, J., Stanton, A. V., Steinthorsdottir, V., Stirrups, K., Stringham, H.M.,
- Sundström, J., Swertz, M.A., Swift, A.J., Syvänen, A.-C., Tan, S.-T., Tayo, B.O., Thorand,
- B., Thorleifsson, G., Tyrer, J.P., Uh, H.-W., Vandenput, L., Verhulst, F.C., Vermeulen,
- S.H., Verweij, N., Vonk, J.M., Waite, L.L., Warren, H.R., Waterworth, D., Weedon, M.N.,
- Wilkens, L.R., Willenborg, C., Wilsgaard, T., Wojczynski, M.K., Wong, A., Wright, A.F.,
- Zhang, Q., Brennan, E.P., Choi, M., Dastani, Z., Drong, A.W., Eriksson, P., Franco-
- Cereceda, A., Gådin, J.R., Gharavi, A.G., Goddard, M.E., Handsaker, R.E., Huang, J.,
- Karpe, F., Kathiresan, S., Keildson, S., Kiryluk, K., Kubo, M., Lee, J.-Y., Liang, L., Lifton,

R.P., Ma, B., McCarroll, S.A., McKnight, A.J., Min, J.L., Moffatt, M.F., Montgomery,

- G.W., Murabito, J.M., Nicholson, G., Nyholt, D.R., Okada, Y., Perry, J.R.B., Dorajoo, R.,
- Reinmaa, E., Salem, R.M., Sandholm, N., Scott, R.A., Stolk, L., Takahashi, A., Tanaka,
- Toshihiro, van't Hooft, F.M., Vinkhuyzen, A.A.E., Westra, H.-J., Zheng, W., Zondervan,
- K.T., Heath, A.C., Arveiler, D., Bakker, S.J.L., Beilby, J., Bergman, R.N., Blangero, J.,
- Bovet, P., Campbell, H., Caulfield, M.J., Cesana, G., Chakravarti, A., Chasman, D.I.,
- Chines, P.S., Collins, F.S., Crawford, D.C., Adrienne Cupples, L., Cusi, D., Danesh, J., de
- Faire, U., den Ruijter, H.M., Dominiczak, A.F., Erbel, R., Erdmann, J., Eriksson, J.G.,
- Farrall, M., Felix, S.B., Ferrannini, E., Ferrières, J., Ford, I., Forouhi, N.G., Forrester, T.,
- Franco, O.H., Gansevoort, R.T., Gejman, P. V., Gieger, C., Gottesman, O., Gudnason, V.,
- Gyllensten, U., Hall, A.S., Harris, T.B., Hattersley, A.T., Hicks, A.A., Hindorff, L.A.,
- Hingorani, A.D., Hofman, A., Homuth, G., Kees Hovingh, G., Humphries, S.E., Hunt, S.C.,
- Hyppönen, E., Illig, T., Jacobs, K.B., Jarvelin, M.-R., Jöckel, K.-H., Johansen, B., Jousilahti,
- P., Wouter Jukema, J., Jula, A.M., Kaprio, J., Kastelein, J.J.P., Keinanen-Kiukaanniemi,
- S.M., Kiemeney, L.A., Knekt, P., Kooner, J.S., Kooperberg, C., Kovacs, P., Kraja, A.T.,
- Kumari, M., Kuusisto, J., Lakka, T.A., Langenberg, C., Le Marchand, L., Lehtimäki, T.,
- Lyssenko, V., Männistö, S., Marette, A., Matise, T.C., McKenzie, C.A., McKnight, B.,
- Moll, F.L., Morris, A.D., Morris, A.P., Murray, J.C., Nelis, M., Ohlsson, C., Oldehinkel,
- A.J., Ong, K.K., Madden, P.A.F., Pasterkamp, G., Peden, J.F., Peters, A., Postma, D.S.,
- Pramstaller, P.P., Price, J.F., Qi, L., Raitakari, O.T., Rankinen, T., Rao, D.C., Rice, T.K.,
- Ridker, P.M., Rioux, J.D., Ritchie, M.D., Rudan, I., Salomaa, V., Samani, N.J., Saramies, J.,
- Sarzynski, M.A., Schunkert, H., Schwarz, P.E.H., Sever, P., Shuldiner, A.R., Sinisalo, J.,
- Stolk, R.P., Strauch, K., Tönjes, A., Trégouët, D.-A., Tremblay, A., Tremoli, E., Virtamo, J.,
- Vohl, M.-C., Völker, U., Waeber, G., Willemsen, G., Witteman, J.C., Carola Zillikens, M.,

Adair, L.S., Amouyel, P., Asselbergs, F.W., Assimes, T.L., Bochud, M., Boehm, B.O.,

- Boerwinkle, E., Bornstein, S.R., Bottinger, E.P., Bouchard, C., Cauchi, S., Chambers, J.C.,
- Chanock, S.J., Cooper, R.S., de Bakker, P.I.W., Dedoussis, G., Ferrucci, L., Franks, P.W.,
- Froguel, P., Groop, L.C., Haiman, C.A., Hamsten, A., Hui, J., Hunter, D.J., Hveem, K.,
- Kaplan, R.C., Kivimaki, M., Kuh, D., Laakso, M., Liu, Y., Martin, N.G., März, W., Melbye,
- M., Metspalu, A., Moebus, S., Munroe, P.B., Njølstad, I., Oostra, B.A., Palmer, C.N.A.,
- Pedersen, N.L., Perola, M., Pérusse, L., Peters, U., Power, C., Quertermous, T., Rauramaa,
- R., Rivadeneira, F., Saaristo, T.E., Saleheen, D., Sattar, N., Schadt, E.E., Schlessinger, D.,
- Eline Slagboom, P., Snieder, H., Spector, T.D., Thorsteinsdottir, U., Stumvoll, M.,
- Tuomilehto, J., Uitterlinden, A.G., Uusitupa, M., van der Harst, P., Walker, M.,
- Wallaschofski, H., Wareham, N.J., Watkins, H., Weir, D.R., Wichmann, H.-E., Wilson, J.F.,
- Zanen, P., Borecki, I.B., Deloukas, P., Fox, C.S., Heid, I.M., O'Connell, J.R., Strachan,
- D.P., Stefansson, K., van Duijn, C.M., Abecasis, G.R., Franke, L., Frayling, T.M.,
- McCarthy, M.I., Visscher, P.M., Scherag, A., Willer, C.J., Boehnke, M., Mohlke, K.L.,
- Lindgren, C.M., Beckmann, J.S., Barroso, I., North, K.E., Ingelsson, E., Hirschhorn, J.N.,

Loos, R.J.F., Speliotes, E.K., 2015. Genetic studies of body mass index yield new insights for obesity biology. Nature 518, 197–206. https://doi.org/10.1038/nature14177

- Lopresti, A.L., 2017. Cognitive behaviour therapy and inflammation: A systematic review of its relationship and the potential implications for the treatment of depression. Aust. New Zeal.
 J. Psychiatry 51, 565–582. https://doi.org/10.1177/0004867417701996
- Löwe, B., Unützer, J., Callahan, C.M., Perkins, A.J., Kroenke, K., 2004. Monitoring Depression Treatment Outcomes With the Patient Health Questionnaire-9. Med. Care 42, 1194–1201. https://doi.org/10.1097/00005650-200412000-00006

- Lynall, M.-E., Turner, L., Bhatti, J., Cavanagh, J., de Boer, P., Mondelli, V., Jones, D., Drevets, W.C., Cowen, P., Harrison, N.A., Pariante, C.M., Pointon, L., Clatworthy, M.R., Bullmore, E., 2020. Peripheral Blood Cell–Stratified Subgroups of Inflamed Depression. Biol. Psychiatry 88, 185–196. https://doi.org/10.1016/j.biopsych.2019.11.017
- Mac Giollabhui, N., Ng, T.H., Ellman, L.M., Alloy, L.B., 2020. The longitudinal associations of inflammatory biomarkers and depression revisited: systematic review, meta-analysis, and meta-regression. Mol. Psychiatry. https://doi.org/10.1038/s41380-020-00867-4
- McIntyre, R.S., Subramaniapillai, M., Lee, Y., Pan, Z., Carmona, N.E., Shekotikhina, M.,
 Rosenblat, J.D., Brietzke, E., Soczynska, J.K., Cosgrove, V.E., Miller, S., Fischer, E.G.,
 Kramer, N.E., Dunlap, K., Suppes, T., Mansur, R.B., 2019. Efficacy of Adjunctive
 Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression. JAMA
 Psychiatry 1–8. https://doi.org/10.1001/jamapsychiatry.2019.0779
- Milaneschi, Y., Kappelmann, N., Ye, Z., Lamers, F., Moser, S., Jones, P.B., Burgess, S., Penninx, B.W.J.H., Khandaker, G.M., 2021a. Association of Inflammation with Depression and Anxiety: Evidence for Symptom-Specificity and Potential Causality from UK Biobank and NESDA Cohorts. medRxiv. https://doi.org/10.1101/2021.01.08.20248710
- Milaneschi, Y., Lamers, F., Berk, M., Penninx, B.W.J.H., 2020. Depression Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic Depression. Biol. Psychiatry 88, 369– 380. https://doi.org/10.1016/j.biopsych.2020.01.014
- Milaneschi, Y., Lamers, F., Bot, M., Drent, M.L., Penninx, B.W.J.H., 2017a. Leptin
 Dysregulation Is Specifically Associated With Major Depression With Atypical Features:
 Evidence for a Mechanism Connecting Obesity and Depression. Biol. Psychiatry 81, 807–

814. https://doi.org/10.1016/j.biopsych.2015.10.023

- Milaneschi, Y., Lamers, F., Penninx, B.W.J.H., 2021b. Dissecting Depression Biological and Clinical Heterogeneity—The Importance of Symptom Assessment Resolution. JAMA Psychiatry 362, 2021. https://doi.org/10.1001/jamapsychiatry.2020.4373
- Milaneschi, Y., Lamers, F., Peyrot, W., Abdellaoui, A., Willemsen, G., Hottenga, J.-J., Jansen,
 R., Mbarek, H., Dehghan, A., Lu, C., 2016. Polygenic dissection of major depression
 clinical heterogeneity. Mol. Psychiatry 21, 516–522. https://doi.org/10.1038/mp.2015.86
- Milaneschi, Y., Lamers, F., Peyrot, W.J., Baune, B.T., Breen, G., Dehghan, A., Forstner, A.J.,
 Grabe, H.J., Homuth, G., Kan, C., Lewis, C., Mullins, N., Nauck, M., Pistis, G., Preisig, M.,
 Rivera, M., Rietschel, M., Streit, F., Strohmaier, J., Teumer, A., Van der Auwera, S., Wray,
 N.R., Boomsma, D.I., Penninx, B.W.J.H., 2017b. Genetic Association of Major Depression
 With Atypical Features and Obesity-Related Immunometabolic Dysregulations. JAMA
 Psychiatry 74, 1214. https://doi.org/10.1001/jamapsychiatry.2017.3016
- Möller, H., 2000. Rating depressed patients: observer- vs self-assessment. Eur. Psychiatry 15, 160–172. https://doi.org/10.1016/S0924-9338(00)00229-7
- Moriarity, D.P., Alloy, L.B., 2021. Back to Basics: The Importance of Measurement Properties in Biological Psychiatry. Neurosci. Biobehav. Rev. 123, 72–82. https://doi.org/10.1016/j.neubiorev.2021.01.008
- Moriarity, D.P., Horn, S.R., Kautz, M.M., Haslbeck, J.M.B., Alloy, L.B., 2020a. How handling extreme C-reactive protein (CRP) values and regularization influences CRP and depression criteria associations in network analyses. Brain. Behav. Immun. https://doi.org/10.1016/j.bbi.2020.10.020

- Moriarity, D.P., van Borkulo, C., Alloy, L.B., 2020b. Inflammatory phenotype of depression symptom structure: A network perspective. Brain. Behav. Immun. 87, S48. https://doi.org/10.1016/j.bbi.2020.12.005
- Nettis, M.A., Lombardo, G., Hastings, C., Zajkowska, Z., Mariani, N., Nikkheslat, N., Worrell, C., Enache, D., McLaughlin, A., Kose, M., Sforzini, L., Bogdanova, A., Cleare, A., Young, A.H., Pariante, C.M., Mondelli, V., 2021. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial. Neuropsychopharmacology 1–10. https://doi.org/10.1038/s41386-020-00948-6
- Ni, G., Zeng, J., Revez, J.A., Wang, Y., Ge, T., Restaudi, R., Kiewa, J., Nyholt, D.R., Coleman, J.R.I., Smoller, J.W., Consortium, S.W.G. of the P.G., Yang, J., Visscher, P.M., Wray, N.R., 2020. A comprehensive evaluation of polygenic score methods across cohorts in psychiatric disorders. medRxiv 1–31.
- Ohlsson, H., Kendler, K.S., 2019. Applying Causal Inference Methods in Psychiatric Epidemiology. JAMA Psychiatry 1–8. https://doi.org/10.1001/jamapsychiatry.2019.3758
- Osimo, E.F., Baxter, L.J., Lewis, G., Jones, P.B., Khandaker, G.M., 2019. Prevalence of lowgrade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol. Med. 49, 1958–1970. https://doi.org/10.1017/S0033291719001454
- Pistis, G., Milaneschi, Y., Vandeleur, C.L., Lasserre, A.M., Penninx, B.W.J.H., Lamers, F.,
 Boomsma, D.I., Hottenga, J., Marques-Vidal, P., Vollenweider, P., Waeber, G., Aubry, J.,
 Preisig, M., Kutalik, Z., 2021. Obesity and atypical depression symptoms: findings from
 Mendelian randomization in two European cohorts. Transl. Psychiatry 11, 96.

https://doi.org/10.1038/s41398-021-01236-7

R Core Team, 2017. R: A language and environment for statistical computing.

- Raison, C.L., Rutherford, R.E., Woolwine, B.J., Shuo, C., Schettler, P., Drake, D.F., Haroon, E., Miller, A.H., 2013. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70, 31–41. https://doi.org/10.1001/2013.jamapsychiatry.4
- Robinaugh, D.J., Hoekstra, R.H.A., Toner, E.R., Borsboom, D., 2020. The network approach to psychopathology: a review of the literature 2008–2018 and an agenda for future research.
 Psychol. Med. 50, 353–366. https://doi.org/10.1017/S0033291719003404
- Rush, A.J., Fava, M., Wisniewski, S.R., Lavori, P.W., Trivedi, M.H., Sackeim, H.A., Thase,
 M.E., Nierenberg, A.A., Quitkin, F.M., Kashner, T.M., Kupfer, D.J., Rosenbaum, J.F.,
 Alpert, J., Stewart, J.W., McGrath, P.J., Biggs, M.M., Shores-Wilson, K., Lebowitz, B.D.,
 Ritz, L., Niederehe, G., for the STAR*D Investigators Group, 2004. Sequenced treatment
 alternatives to relieve depression (STAR*D): rationale and design. Control. Clin. Trials 25,
 119–142. https://doi.org/10.1016/S0197-2456(03)00112-0
- Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden, D.,
 Niederehe, G., Thase, M.E., Lavori, P.W., Lebowitz, B.D., McGrath, P.J., Rosenbaum, J.F.,
 Sackeim, H.A., Kupfer, D.J., Luther, J., Fava, M., 2006. Acute and Longer-Term Outcomes
 in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report.
 Am. J. Psychiatry 163, 1905–1917. https://doi.org/10.1176/appi.ajp.163.11.1905
- Simmons, W.K., Burrows, K., Avery, J.A., Kerr, K.L., Taylor, A., Bodurka, J., Potter, W., Teague, T.K., Drevets, W.C., 2018. Appetite changes reveal depression subgroups with

distinct endocrine, metabolic, and immune states. Mol. Psychiatry 1–12. https://doi.org/10.1038/s41380-018-0093-6

- Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., Liu, B., Matthews, P., Ong, G., Pell, J., Silman, A., Young, A., Sprosen, T., Peakman, T., Collins, R., 2015. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLOS Med. 12, e1001779. https://doi.org/10.1371/journal.pmed.1001779
- Timpson, N.J., Nordestgaard, B.G., Harbord, R.M., Zacho, J., Frayling, T.M., Tybjærg-Hansen, A., Davey Smith, G., 2011. C-reactive protein levels and body mass index: elucidating direction of causation through reciprocal Mendelian randomization. Int. J. Obes. 35, 300– 308. https://doi.org/10.1038/ijo.2010.137
- van Borkulo, C., Boschloo, L., Borsboom, D., Penninx, B.W.J.H., Waldorp, L.J., Schoevers,
 R.A., 2015. Association of Symptom Network Structure With the Course of Depression.
 JAMA Psychiatry 72, 1219–1226. https://doi.org/10.1001/jamapsychiatry.2015.2079
- van Eeden, W.A., van Hemert, A.M., Carlier, I.V.E., Penninx, B.W.J.H., Lamers, F., Fried, E.I., Schoevers, R., Giltay, E.J., 2020. Basal and LPS-stimulated inflammatory markers and the course of individual symptoms of depression. Transl. Psychiatry 10, 235. https://doi.org/10.1038/s41398-020-00920-4
- White, J., Kivimäki, M., Jokela, M., Batty, G.D., 2017. Association of inflammation with specific symptoms of depression in a general population of older people: The English Longitudinal Study of Ageing. Brain. Behav. Immun. 61, 27–30. https://doi.org/10.1016/j.bbi.2016.08.012

- Williams, D.R., Rhemtulla, M., Wysocki, A.C., Rast, P., 2019. On Nonregularized Estimation of Psychological Networks. Multivariate Behav. Res. 0, 1–23. https://doi.org/10.1080/00273171.2019.1575716
- Wittenberg, G.M., Stylianou, A., Zhang, Y., Sun, Y., Gupta, A., Jagannatha, P.S., Wang, D., Hsu, B., Curran, M.E., Khan, S., Chen, G., Bullmore, E.T., Drevets, W.C., 2020. Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders. Mol. Psychiatry 25, 1275–1285. https://doi.org/10.1038/s41380-019-0471-8
- Wray, N.R., Lin, T., Austin, J., McGrath, J.J., Hickie, I.B., Murray, G.K., Visscher, P.M., 2020. From Basic Science to Clinical Application of Polygenic Risk Scores: A Primer. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2020.3049

TABLES & FIGURES

Tables

Table 1. Baseline characteristics of MARS, STAR*D, and UK Biobank samples

	MARS	STAR*D	UK Biobank
N	1,058	1,143	110,010
Sex			
Women, N (%)	563 (53.2%)	676 (59.1%)	61,212 (55.6%)
Men, N (%)	495 (46.8%)	467 (40.9%)	48,798 (44.4%)
Age in years			
Mean (SD)	47.8 (14.4)	43.2 (13.6)	56.2 (7.7)
Range	18-87	18-75	39-72
Study location	Germany	United States	United Kingdom
Study population	MDD inpatients	MDD outpatients	General population
CRP PRS	1.	1	1 1
Mean (SD)	-0.01 (1.00)	0.00 (1.00)	-0.01 (1.00)
Range	-3.14-3.15	-3.21-2.94	-4.58-4.21
IL-6 PRS			
Mean (SD)	0.00 (1.00)	0.00 (1.00)	0.00 (1.00)
Range	-3.33-3.34	-3.41-3.94	-4.07-3.92
IL-10 PRS			
Mean (SD)	0.00 (1.00)	0.00 (1.00)	0.00 (1.00)
Range	-3.11-3.24	-3.28-3.13	-4.35-4.60
TNF-a PRS	0.00 (1.00)	0.00 (1.00)	0.00 (1.00)
Mean (SD)	0.00 (1.00)	0.00 (1.00)	0.00 (1.00)
Range	-3.01-3.07	-3.33-3.32	-4.1/-4.51
BMI PRS	0.02(1.01)	0.00(1.00)	0.04(1.00)
Read	-0.02 (1.01)	-3.04-3.20	-0.04 (1.00)
PHO_{-9} sum-score	-3.02-4.00	-5.04-5.20	
Mean (SD)	_	_	27(36)
Panga	-	-	0.27
\mathbf{Minge}	-	-	351 (0 3)
Missing, N (%)	-	-	551 (0.5)
HAM-D sull-score	22.8(5.0)	22.4(4.0)	
Mean (SD)	23.8 (3.9)	22.4 (4.9)	-
Range	5-42	13-38	-
Missing, N (%)	6 (0.6%)	0(0%)	-
Depressed mood			
Mean (SD)	3.05 (0.88)	2.59 (0.77)	0.23 (0.56)
Range	0-4	0-4	0-3
Anhedonia			
Mean (SD)	3.63 (0.68)	2.54 (0.76)	0.26 (0.56)
Range	0-4	0-4	0-3
Sleep problems			
Mean (SD)	3.46 (2.00)	3.42 (1.77)	0.71 (0.99)
Range	0-6	0-6	0-3

	MARS	STAR*D	UK Biobank
Fatigue			
Mean (SD)	1.49 (0.68)	1.68 (0.55)	0.66 (0.81)
Range	0-2	0-2	0-3
Changes in appetite			
Mean (SD)	0.77 (0.66)	0.68 (0.80)	0.25 (0.62)
Range	0-2	0-2	0-3
Psychomotor changes			
Mean (SD)	1.44 (0.96)	1.42 (0.72)	0.07 (0.34)
Range	0-4	0-4	0-3
Suicidality			
Mean (SD)	1.35 (1.15)	0.94 (0.85)	0.05 (0.28)
Range	0-4	0-4	0-3
~			

Note: MDD=Major Depressive Disorder, SD=Standard deviation, PHQ-9=Patient Health Questionnaire-9, HAM-D=Hamilton Rating Scale for Depression.

	MARS		STAR*D		UK Biobank		
PRS-symptom edges	FGL (C1)	Model search (C3)	FGL (C1)	Model search (C3)	FGL (C1)	Model search (C3)	FGL consistency (C2)
CRP							
Anhedonia	-0.016 (67%)		-0.043 (95%)		-0.002 (60%)		Yes
Depressed mood	-0.009 (57%)		0.045 (94%)				
Sleep problems [*]	-0.02 (75%)		0.031 (84%)				
Fatigue	0.053 (98%)		0.025 (79%)		0.011 (100%)		Yes
Changes in appetite [*]	-0.034 (89%)		-0.043 (94%)		0.003 (91%)	0.013 (73%)	Yes
Psychomotor changes	0.039 (91%)		0.001 (53%)				
Suicidality	-0.02 (74%)		-0.038 (88%)				
IL-6							
Anhedonia	-0.047 (97%)						
Depressed mood	-0.001 (52%)						
Sleep problems [*]			-0.02 (82%)				
Fatigue	0.012 (72%)						
Changes in appetite [*]	-0.032 (87%)		0.032 (85%)				
Psychomotor changes							
Suicidality	0.053 (95%)		-0.029 (83%)				
IL-10							
Anhedonia	0.008 (67%)		-0.005 (66%)				
Depressed mood			-0.002 (52%)				
Sleep problems [*]			0.014 (72%)				
Fatigue			0.007 (66%)				
Changes in appetite [*]	0.021 (80%)						
Psychomotor changes	0.015 (66%)		0.033 (90%)				
Suicidality			0.054 (99%)				
TNF-a							
Anhedonia	0.054 (96%)		0.013 (66%)				
Depressed mood	-0.017 (66%)		-0.017 (75%)				
Sleep problems [*]	-0.005 (57%)		0.005 (68%)				
Fatigue	0.016 (65%)		0.032 (91%)		0.002 (58%)		Yes
Changes in appetite [*]	-0.015 (70%)		0.023 (75%)				

Table 2. PRS-symptom edge consistency criteria (C) across network analyses

	MARS		STAR*D		UK Biobank		
PRS-symptom edges	FGL (C1)	Model search (C3)	FGL (C1)	Model search (C3)	FGL (C1)	Model search (C3)	FGL consistency (C2)
Psychomotor changes	0.008 (63%)		0.008 (59%)				
Suicidality			0.047 (94%)				
BMI							
Anhedonia	0.036 (91%)		0.033 (86%)			-0.010 (63%)	
Depressed mood							
Sleep problems [*]	0.06 (99%)		0.055 (97%)				
Fatigue	-0.016 (74%)						
Changes in appetite [*]			-0.031 (87%)		0.054 (100%)	0.066 (100%)	
Psychomotor changes	0.003 (55%)		-0.023 (83%)				
Suicidality	0.021 (75%)		0.04 (91%)				

Note: Cell values reflect edge weights (i.e., partial correlation coefficients) and the percentage of 500 bootstrap estimations that edges were present. Estimates are restricted to those edges, for which >50% of bootstrapped samples were non-zero and directionally consistent (i.e., criteria 1 & 3). ^{*}Changes in appetite and sleep problems are measured as composite symptoms in UK Biobank, but as loss of appetite and insomnia in MARS and STAR*D samples.

Figure Titles and Legends

Figure 1. Study design and analysis pipeline

Legend: BIC=Bayesian information criterion; CV=cross-validation; PC=principal component (or multi-dimensional scaling component used for MARS & STAR*D); \Box =PRS-CS tuning parameter.

Figure 2. Estimated FGL networks across samples

Legend: Networks are visualised with the *qgraph* package. Blue lines indicate positive and red lines negative associations, respectively, with larger associations displayed with thicker lines. Circles around nodes display node predictability, which can be interpreted similar to explained variance. Maximum size of edge associations is 0.55. As the primary focus of this investigation was to identify consistent PRS-symptom associations, we manually unfaded edges between PRSs and symptoms if these edges met quality criteria 1 and 2 (see Table 2). Changes in appetite and sleep problems are measured as composite symptoms in UK Biobank, but as loss of appetite and insomnia in MARS and STAR*D samples.

Figure 3. Bootstrapped 95% quantile intervals of PRS-symptom edges using FGL estimation

Legend: Bootstrapped 95% quantile intervals (i.e., 95% of the distribution of raw bootstrapped edge estimates) are highlighted as shaded area for each edge. Black points indicate the raw FGL sample estimate while red points indicate the raw bootstrapped mean estimate. Edges are indicated on the y-axis and sorted by mean edge weight across samples in descending order.









- A: Depressive Symptoms
- 1: Depressed mood
- 2: Anhedonia
- 3: Sleep problems
- 4: Fatigue
- 5: Changes in appetite
- 6: Psychomotor changes
- 7: Suicidality

B: Polygenic Risk Scores

- 8: CRP
- 9: IL-6
- 10: IL-10
- 11: TNF-a
- 12: BMI





